Bergisch Gladbach, Germany

Jutta Kollet

This inventor holds 1 USPTO granted patent. Top assignee: Miltenyi Biotec B.v. & Co. Kg. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jutta Kollet. Retrieved from https://idiyas.com/inventor/jutta-kollet-lcy95a6i

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jutta Kollet: Innovator in Cancer Treatment

Introduction

Jutta Kollet is a prominent inventor based in Bergisch Gladbach, Germany. She has made significant contributions to the field of cancer treatment through her innovative research and development.

Latest Patents

Jutta Kollet holds a patent for "Compositions and Methods for Treating Cancer Expressing CD90 and CD326." This patent represents her commitment to advancing medical science and improving treatment options for cancer patients. She has 1 patent to her name.

Career Highlights

Kollet is currently associated with Miltenyi Biotec B.V. & Co. KG, where she continues to work on groundbreaking research. Her career is marked by a dedication to developing effective therapies that can make a difference in the lives of patients.

Collaborations

Throughout her career, Jutta has collaborated with notable colleagues, including Christoph Herbel and Dominik Eckardt. These partnerships have enhanced her research efforts and contributed to the success of her projects.

Conclusion

Jutta Kollet is a trailblazer in the field of cancer treatment, with a focus on innovative solutions that address critical medical challenges. Her work exemplifies the impact of dedicated inventors in advancing healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…